Newly diagnosed versus relapsed idiopathic thrombotic thrombocytopenic purpura: A comparison of presenting clinical characteristics and response to treatment

Annals of Hematology

Volumn 88, Issue 10, 2009, Pages 973-978

  Alvarez Larrán, Alberto ^a   del Río Garma, Julio ^b   Pujol, Misericòrdia ^c   Rubia, Javier ^d   Hernández Jodra, Manuel ^e   Borrell, Montserrat ^f   González Porras, José R ^g   García Gala, José M ^h   Viejo, Aurora ⁱ   Enríquez, Lourdes ^j   Arbona, Cristina ^k   García Erce, José A ^l   Noblejas, Ana G ^m   Pereira, Arturo ⁿ  

^a HOSPITAL DEL MAR   (Spain)

^b Complexo H Universitario ^*  (Spain)

^c BANC DE SANG I TEIXITS   (Spain)

^d HOSPITAL UNIVERSITARIO LA FE   (Spain)

^e HOSPITAL RAMÓN Y CAJAL   (Spain)

^f HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^g HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^h HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

ⁱ HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^j HOSPITAL DO MEIXOEIRO   (Spain)

^k HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^l HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^m HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

ⁿ HOSPITAL CLÍNIC   (Spain)

more..

Author keywords

ADAMTS13; Plasma exchange; Relapse; Thrombotic thrombocytopenic purpura

Indexed keywords

CORTICOSTEROID; LACTATE DEHYDROGENASE; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; ENZYME BLOOD LEVEL; FEMALE; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; MAJOR CLINICAL STUDY; MALE; PLASMAPHERESIS; PRIORITY JOURNAL; RELAPSE; REMISSION; SPLENECTOMY; TREATMENT RESPONSE;

ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; AGED; COHORT STUDIES; FEMALE; FEVER; HEMOGLOBINS; HUMANS; L-LACTATE DEHYDROGENASE; MALE; MIDDLE AGED; NERVOUS SYSTEM DISEASES; PLASMA EXCHANGE; PROSPECTIVE STUDIES; PURPURA, THROMBOTIC THROMBOCYTOPENIC; RECURRENCE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 69249216745     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-009-0707-9     Document Type: Article

References (25)

1. Aqui NA, Stein SH, Konkle BA, Abrams CS, Strobl FJ (2003) Role of splenectomy in patients with refractory or relapsed thrombotic thrombocytopenic purpura. J Clin Apher 18:51-54. doi: 10.1002/jca.10053
2. Bianchi V, Robles R, Alberio L, Furlan M, Lammle B (2002) Von Willebrand factor-cleaving protease (ADAMTS13) in thrombocytopenic disorders: A severely deficient activity is specific for thrombotic thrombocytopenic purpura. Blood 100:710-713. doi: 10.1182/blood-2002-02-0344
3. Cohen JA, Brecher ME, Bandarenko N (1998) Cellular source of serum lactate dehydrogenase elevation in patients with thrombotic thrombocytopenic purpura. J Clin Apher 13:16-19. doi: 10.1002/(SICI) 1098-1101(1998) 13:1<16::AID-JCA3>3.0.CO;2-C
4. Del Rio-Garma J, Alvarez-Larran A, Martinez C, Muncunill J, Castella D, de la RJ et al. (2008) Methylene blue-photoinactivated plasma versus quarantine fresh frozen plasma in thrombotic thrombocytopenic purpura: A multicentric, prospective cohort study. Br J Haematol 143:39-45
5. Dervenoulas J, Tsirigotis P, Bollas G, Pappa V, Xiros N, Economopoulos T et al (2000) Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS): Treatment outcome, relapses, prognostic factors. A single-center experience of 48 cases. Ann Hematol 79:66-72. doi: 10.1007/ s002770050012
6. Ferrari S, Scheiflinger F, Rieger M, Mudde G, Wolf M, Coppo P et al (2007) Prognostic value of anti-ADAMTS 13 antibody features (Ig isotype, titer, and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with undetectable ADAMTS 13 activity. Blood 109:2815-2822
7. Forzley BR, Sontrop JM, Macnab JJ, Chen S, Clark WF (2008) Treating TTP/ HUS with plasma exchange: A single centre's 25-year experience. Br J Haematol 143:100-106
8. George JN (2000) How I treat patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Blood 96:1223-1229
9. Gerritsen HE, Turecek PL, Schwarz HP, Lammle B, Furlan M (1999) Assay of von Willebrand factor (vWF)-cleaving protease based on decreased collagen binding affinity of degraded vWF: A tool for the diagnosis of thrombotic thrombocytopenic purpura (TTP). Thromb Haemost 82:1386-1389
10. Kremer Hovinga JA, Studt JD, Demarmels BF, Solenthaler M, Alberio L, Zwicky C et al (2004) Splenectomy in relapsing and plasma-refractory acquired thrombotic thrombocytopenic purpura. Haematologica 89:320-324
11. Mannucci PM, Peyvandi F (2007) TTP and ADAMTS13: When is testing appropriate? Hematology (Am Soc Hematol Educ Program) 121-126. doi: 10.1182/asheducation-2007.1.121
12. Pereira A, Mazzara R, Monteagudo J, Sanz C, Puig L, Martinez A et al (1995) Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome: A multivariate analysis of factors predicting the response to plasma exchange. Ann Hematol 70:319-323. doi: 10.1007/BF01696619
13. Peyvandi F, Lavoretano S, Palla R, Feys HB, Vanhoorelbeke K, Battaglioli T et al (2008) ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission. Haematologica 93:232-239. doi: 10.3324/haematol.11739
14. Ridolfi RL, Bell WR (1981) Thrombotic thrombocytopenic purpura. Report of 25 cases and review of the literature. Medicine (Baltimore) 60:413-428. doi: 10.1097/00005792-198111000-00003
15. Rock G, Porta C, Bobbio-Pallavicini E (2000) Thrombotic thrombocytopenic purpura treatment in year 2000. Haematologica 85:410-419
16. Rock GA, Shumak KH, Buskard NA, Blanchette VS, Kelton JG, Nair RC et al (1991) Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med 325:393-397
17. Rose M, Eldor A (1987) High incidence of relapses in thrombotic thrombocytopenic purpura. Clinical study of 38 patients. Am J Med 83:437-444. doi: 10.1016/0002-9343(87) 90753-4
18. Sadler JE, Moake JL, Miyata T, George JN (2004) Recent advances in thrombotic thrombocytopenic purpura. Hematology (Am Soc Hematol Educ Program) 407-423. doi: 10.1182/asheducation-2004.1.407
19. Sarode R, Gottschall JL, Aster RH, McFarland JG (1997) Thrombotic thrombocytopenic purpura: Early and late responders. Am J Hematol 54:102-107. doi: 10.1002/(SICI) 1096-8652(199702) 54:2<102::AID-AJH2>3.0.CO;2-0
20. Scully M, Yarranton H, Liesner R, Cavenagh J, Hunt B, Benjamin S et al (2008) Regional UK TTP Registry: Correlation with laboratory ADAMTS 13 analysis and clinical features. Br J Haematol 142:819-826. doi: 10.1111/ j.1365-2141.2008.07276.x
21. Shumak KH, Rock GA, Nair RC (1995) Late relapses in patients successfully treated for thrombotic thrombocytopenic purpura. Canadian Apheresis Group. Ann Intern Med 122:569-572
22. Vesely SK, George JN, Lammle B, Studt JD, Alberio L, El-Harake MA et al (2003) ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: Relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood 102:60-68. doi: 10.1182/blood-2003-01-0193
23. Willis MS, Bandarenko N (2005) Relapse of thrombotic thrombocytopenic purpura: Is it a continuum of disease? Semin Thromb Hemost 31:700-708. doi: 10.1055/s-2005-925476
24. Yomtovian R, Niklinski W, Silver B, Sarode R, Tsai HM (2004) Rituximab for chronic recurring thrombotic thrombocytopenic purpura: A case report and review of the literature. Br J Haematol 124:787-795. doi: 10.1111/ j.1365-2141.2004.04836.x
25. Zheng XL, Kaufman RM, Goodnough LT, Sadler JE (2004) Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura. Blood 103:4043-4049. doi: 10.1182/ blood-2003-11-4035